Carfilzomib

Adults: Hydration: Make sure the patient is well hydrated before Carfilzomib is given in Cycle 1, especially when there is a high risk of tumor lysis syndrome (TLS) or renal toxicity. Consider both oral fluids (30 mL per kg at least 48 hours before Cycle 1, Day 1) and intravenous fluids (250 mL to 500 mL of a suitable intravenous fluid before each dose in Cycle 1). If needed, give another 250 mL to 500 mL of intravenous fluids after the dose. In later cycles, continue oral and/or intravenous hydration as needed. Watch the patient for signs of volume overload and adjust the fluids to what each patient needs, particularly in those with cardiac failure or at risk of it. Premedications and Concomitant Medications: Give the recommended dose of dexamethasone, whether it is for monotherapy or as part of the combination therapy. Give it orally or intravenously at least 30 minutes but no more than 4 hours before every dose of Carfilzomib in Cycle 1, to reduce how often infusion-related reactions occur and how severe they are. If these symptoms occur in later cycles, start the dexamethasone premedication again. Provide thromboprophylaxis for patients who receive Carfilzomib together with other therapies. Consider antiviral prophylaxis to lower the risk of herpes zoster reactivation. Electrolyte Monitoring: Check serum potassium levels regularly during treatment.